Observed Signal · Nov 3, 2026 · earnings · Source: SEC API · Impact: 4.1/5

Clarivate Furnishes Q3 2026 Earnings Release and Supplemental Financial Information

Executive Signal Summary

Clarivate Plc filed a Form 8-K under Items 2.02 and 7.01 on November 3, 2026, announcing its third-quarter financial results for the period ended September 30, 2026. Along with the earnings release furnished as Exhibit 99.1, the company posted supplemental information detailing revenue, earnings, and financial guidance as Exhibit 99.2 on its investor relations website.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

This is a standard Item 2.02/7.01 notification furnishing Q3 2026 earnings and guidance materials without containing the primary financial tables inside the 8-K body itself.

SIGNAL RADAR

Track Clarivate Signals & Market Shifts in Real-Time

Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.

Start Monitoring
Verified primary sourcesAutomated briefingsInstant watchlist setup

Key Takeaways & Evidence Grounding

  • Clarivate reported Q3 2026 results for the period ended September 30, 2026, via an Item 2.02 earnings announcement.
  • Supplemental information addressing revenue performance, earnings, and guidance was provided under Item 7.01.
  • Exhibits 99.1 (earnings press release) and 99.2 (supplemental data) were furnished rather than filed.
  • Q3 2026 continuing operations revenue stood at $481.6 million compared to $530.3 million in Q3 2025, reflecting product wind-downs despite 1.3% organic recurring revenue growth.
  • Total consolidated net loss was $80.8 million, driven by a $26.4 million loss from continuing operations and a $54.4 million loss from discontinued operations.
  • Life Sciences & Healthcare segment sale closed on October 6, 2026, delivering $488.4 million in net cash, a $75.0 million senior note, and $25.0 million in deferred cash.
  • During the first nine months of 2026, Clarivate retired $192.6 million in notes for $184.2 million in cash and redeemed $100.0 million in 2026 notes.
Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: SEC API•Published: Nov 3, 2026

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

M&A & Corporate FinanceNov 12, 2026

Clarivate Announces Expiration and Results of Debt Tender Offers

On November 12, 2026, Clarivate Plc filed a Form 8-K under Item 8.01 announcing the expiration and final results of previously initiated cash tender offers for certain debt securities. The tender offers were executed through its wholly-owned subsidiary, Clarivate Science Holdings Corporation. The filing incorporates a press release detailing the conclusion of the debt retirement program, supporting the company's broader balance sheet and capital structure management.

Read assessment
financialsNov 10, 2026

8-K Financial Filing Analysis for Clarivate (2026-11-10)

On November 10, 2026, Clarivate Plc filed a Form 8-K announcing the pricing terms for previously announced cash tender offers conducted by its wholly owned subsidiary, Clarivate Science Holdings Corporation, to repurchase certain outstanding debt securities. The filing incorporates by reference a press release detailing the pricing mechanism and tender conditions as Exhibit 99.1. This transaction reflects ongoing active balance sheet management and debt profile optimization following Clarivate's historical debt-financed acquisition strategy.

Read assessment
M&A & Corporate FinanceNov 4, 2026

Clarivate Announces Cash Tender Offers for Outstanding Debt Securities

On November 4, 2026, Clarivate Plc filed a Form 8-K reporting that its wholly owned subsidiary, Clarivate Science Holdings Corporation, launched cash tender offers to repurchase certain of its outstanding debt securities. The filing incorporates by reference a press release issued on the same date detailing the tender offers. This transaction represents an active liability management effort intended to optimize Clarivate's balance sheet, manage debt maturities, or lower aggregate interest expense across its capital structure.

Read assessment
Executive Briefing & Watchlist

Receive all future signals for Clarivate & competitors in your briefing

Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.

Daily primary source scansCurated executive briefingsUnsubscribe anytime